We don't normally get excited about newly launched funds that don't have much of a record, but in the case of the WF Asia Fund, we'll make an exception.

FORBES: Classic Hedge, Asian Flavor

Critics of the deal say that it's more about financial engineering than drug development. (See " Abbott's Solvay Deal: Don't Get Too Excited").

FORBES: Magazine Article

Meanwhile, City traders are a pragmatic bunch and don't get too excited about all this hot air about bonuses.

BBC: City Diaries: 15 October